Reading view

‘We’re not doing 30 bets a year’: Vijay Pande on betting small after running $4B at a16z

Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.
  •  

Why is the DOJ investigating Andreessen Horowitz’s board seats?

Andreessen Horowitz has two partners sitting on the boards of companies that now compete with each other: Ben Horowitz at Databricks and Martin Casado at Fivetran. Nothing too scandalous on the surface, except the Department of Justice has reportedly been investigating the arrangement for almost a year, dusting off a 112-year-old antitrust law that’s rarely used against VCs.  Board conflicts aren’t exactly new, and these companies weren’t necessarily direct competitors when a16z first invested […]
  •  
❌